Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials
A glycoengineered Pichia pastoris host was used to produce an IgG1 with either
afucosylated N-glycosylation (afucosylated biantennary complex) or without N-glycosylation
(N297A) while a wild type P. pastoris host was used to produce an IgG1 containing fungal-
type N-and O-linked glycosylation. The PK properties of these antibodies were compared to
a commercial IgG1 produced in CHO cells following intravenous administration in wild type
C57B6, FcγR-/-or hFcRn transgenic mice. MAbs produced in glycoengineered yeast …
afucosylated N-glycosylation (afucosylated biantennary complex) or without N-glycosylation
(N297A) while a wild type P. pastoris host was used to produce an IgG1 containing fungal-
type N-and O-linked glycosylation. The PK properties of these antibodies were compared to
a commercial IgG1 produced in CHO cells following intravenous administration in wild type
C57B6, FcγR-/-or hFcRn transgenic mice. MAbs produced in glycoengineered yeast …